BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

InKine Pharmaceutical Company, Inc. (INKP) Announces Positive Phase 3 Study Results Of Next Generation Purgative Product - INKP-102


10/19/2005 5:12:47 PM

BLUE BELL, Pa.--(BUSINESS WIRE)--Feb. 22, 2005--InKine Pharmaceutical Company, Inc. (Nasdaq:INKP) today announced positive results of the Company's multicenter, Phase 3 study of its next generation sodium phosphate tablet, INKP-102. The recently completed, randomized, investigator blinded non-inferiority Phase 3 study included 706 adults who underwent colonoscopy. Patients received either 32 tablets ("reduced-dose") or 40 tablets ("comparator dose") of INKP-102 or the FDA-approved dose of 40 Visicol(R) tablets. Both of the INKP-102 arms utilized a dosing schedule that was of shorter duration, more convenient, and less complicated than the Visicol(R) dosing regimen. Approximately 25% of patients in the study were at least 65 years old and the study population included slightly more women than men and included all major U.S. ethnic groups.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->